Pharmacist Moms Group^™

Joseph Rossano, MD, MS, says the crossover cohort shows the 28-week SCOUT-HCM results were no fluke, with benefits replicated in a second group.

The 3 panelists describe how they adjust heart failure, antihypertensive, anticoagulant, and antiarrhythmic therapy during pregnancy and after delivery, and why shared decision-making on lactation should start before delivery.

The panelists call for dedicated research, registries, and better training on medication safety in pregnancy and lactation, and describe how pharmacists can help prevent patients from stopping necessary therapy.

Two pharmacists discuss complexities patients face when starting specialty medications and predict how CVS’s restructuring and reduced specialty pharmacy lock-in may improve affordability and choice.

Delayed NGS results, incomplete community workups, and limited infusion chair availability slow the path from diagnosis to treatment, leaving newly diagnosed patients waiting at a vulnerable time.

Only direct comparative evidence would likely shift first-line choices, yet subcutaneous formulations, reimbursement, payer preferences, and operational efficiency could influence which checkpoint inhibitor treatment teams select.

Navdeep Tangri, MD, PhD, FRCP, explains how flagging roughly 3 in 10 patients as high risk prompted physicians to increase use of guideline-directed therapy.

In a Pulsepoint interview with Pharmacy Times, Jennifer MacDonald, PharmD, BCOP, discusses ovarian cancer guideline updates and pharmacists’ role in selecting therapies, managing toxicities, and preserving patients’ quality of life.

Three experts say that misconceptions and fear can lead patients to stop lifesaving cardiac medications during pregnancy, and they explain how to weigh risks and benefits with reliable resources.